Stay updated with breaking news from Kilpest india. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Brokerage firm Nuvama expects Kilpest India to sustain healthy growth in the molecular diagnostics business, led by product launches, acquisition of new customers, and geographical expansion. The brokerage has a “buy” rating on the stock with a price target of Rs 1,184. This implies an upside potential of 57% from the current levels. ....
/PRNewswire/ The "In Vitro Diagnostics Market - Global Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com s offering. The global. ....
/PRNewswire/ According to Arizton s latest research report, the in-vitro diagnostics market will grow at a CAGR of 3.3% from 2022-2028. In recent years, IVD. ....